ONCAlert | Upfront Therapy for mRCC

Dr. Fleming Shares Encouraging Data With Antiandrogen Therapies in Prostate Cancer

Mark T. Fleming, MD
Published Online: 4:18 PM, Thu March 28, 2019

Mark T. Fleming, MD, medical oncologist, Virginia Oncology Associates, The US Oncology Research, discusses exciting data seen with antiandrogen agents for the treatment of prostate cancer.

Darolutamide, enzalutamide (Xtandi), and apalutamide (Erleada) have all demonstrated promising findings, signifying that therapies are moving forward in this space. It is exciting to see that patients now have a lot of options, Fleming says.

Similar to having several pairs of black shoes and choosing the right pair for the right occasion, Fleming says patients with prostate cancer will have different therapy options for different situations.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.